eligibility_summary
Eligible: adults (≥18) with CTCL per EORTC 2017 who failed ≥1 systemic therapy and received mogamulizumab in post-approval routine care at the approved dose (1 mg/kg IV: D1,8,15,22 cycle 1, D1,15 thereafter), with first dose between Jan 1, 2021 and Jan 31, 2023, and complete medical records. Exclude: any patient not meeting these criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study type: multicenter observational, real-world in Italy, patients with relapsed/refractory CTCL (mycosis fungoides/Sézary) treated with standard-dose mogamulizumab. Drug/intervention: Mogamulizumab—humanized IgG1 monoclonal antibody immunotherapy targeting CCR4 (C-C chemokine receptor 4). Mechanism: binds CCR4 on malignant skin-homing T cells and on CCR4+ regulatory/Th2 T cells, triggering antibody-dependent cellular cytotoxicity (ADCC) via NK-cell Fcγ receptors, depleting CCR4+ cells, reducing Tregs, and enhancing anti-tumor immunity. Cells/pathways targeted: CCR4+ CTCL cells (MF/Sézary), CCR4+ Tregs/Th2, CCR4–CCL17/CCL22 chemokine axis, ADCC effector pathway. Objective: describe activity and safety in routine practice.